Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 9Leukemia, Myeloid, Acute 8Leukemia, Myelomonocytic, Chronic 4Thrombocytosis 1Thrombocythemia, Essential 1Renal Insufficiency 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Liver Diseases 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hypereosinophilic Syndrome 1

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Watchful Waiting 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × pevonedistat × Myeloid × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡